EGFR and non-small cell lung carcinoma: Human epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, and afatinib, can be used in NSCLC patients with activating EGFR receptor mutations (Akamatsu et al., 2019).